ALSO READZydus Cadila receives final approval for Cyproheptadine Hydrochloride Tablets USP Zydus Cadila receives final approval for Felbamate Tablets Zydus Cadila gets USFDA approval to market Mesalamine Delayed - Release Tablets USP, 1.2 g Zydus Cadila receives USFDA approval Zydus receives final approval for Olmesartan Medoxomil Tablets
From USFDAZydus Cadila has received the final approval from the USFDA to market Acyclovir for Injection USP in strengths of 500 mg/vial and 100 mg/vial.
Acyclovir for Injection USP which caters to anti-viral segment, will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)